文献速递妇科

2023年FIGO子宫内膜癌分期系统:革命的演进

2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
PubMed 文献 · Gynecol Oncol · 2024-03-06

本文阐述2023年FIGO子宫内膜癌分期系统的制定依据,该系统整合解剖、组织病理和分子特征,将旧知识与新证据协调统一,从纯解剖边界分期转向整合肿瘤生物学的分期,以更准确预测预后并识别治疗相关亚组。

要点

  • 2023年FIGO子宫内膜癌分期整合解剖、组织病理和分子特征。
  • 该系统旨在提高预后预测准确性并识别治疗相关亚组。
  • 淋巴血管间隙浸润和分子分型等肿瘤生物学标志物被纳入分期。

核心结论

  • 2023年FIGO子宫内膜癌分期系统协调并整合了解剖、组织病理和分子特征的旧知与新识。
  • 该系统要求从传统纯解剖边界分期转变为整合解剖边界与肿瘤生物学的分期系统。

研究设计与样本

  • 本文为国际妇产科联盟(FIGO)2023年子宫内膜癌分期系统的制定依据阐述。

主要发现

  • 自FIGO 2009年分期系统发布14年来,对子宫内膜癌生物学和自然史的理解发生了根本性转变。
  • 2013年TGCA结果及此后多项验证报告表明,「子宫内膜癌」至少由四种分子学定义的不同疾病组成。
  • 淋巴血管间隙浸润等反映肿瘤生物学的强组织病理标志物已被识别。
  • 在分子亚型/淋巴血管间隙浸润等主导性肿瘤生物学标志物存在时,解剖边界对子宫内膜癌患者的预后相关性被显示丧失。

关键数值与推荐

  • 2023年FIGO子宫内膜癌分期系统整合解剖、组织病理和分子特征。
  • 该系统旨在为子宫内膜癌患者提供高准确度的预后预测并识别不同的治疗相关亚组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Embracing the complex and diverse nature of the heterogenous group of malignancies that are included under the umbrella of "endometrial cancer" (EC) to better align prognosis with treatment recommendations, requires a more comprehensive staging system. Our goal at the development of the new FIGO staging was to provide 1) high accuracy in the predictive prognosis for a patient with EC, which is the genuine purpose of a staging system, and 2) identification of distinct treatment relevant subgroups. Since the publication of the 2009 staging system by the International Federation of Gynecology and Obstetrics (FIGO) 14 years ago (1, 2), our understanding of the biology and natural history of EC has undergone a radical transformation. The TGCA results in 2013 (3), and the many validation reports published since then (4-9), have taught us that "EC" is composed of at least four distinct molecularly defined diseases. Strong histopathologic markers reflecting tumor biology such as lymph vascular space invasion (LVSI) were identified. Importantly, anatomical borders were shown to lose their prognostic relevance for EC patients in the presence of dominant tumor biology-markers such as molecular subtypes/LVSI (10, 11). This emphasizes the integration of these novel markers into a prognostic staging system that aims to be relevant to patients. The 2023 FIGO staging system for EC harmonizes and integrates old and new knowledge on anatomic, histopathologic, and molecular features (12). It requires a change in our perception of a staging system, from a traditional purely anatomical borders-based system to an integrated staging system integrating anatomical borders and tumor biology as pivotal prognostic factors for EC patients while providing important information for treatment decision making. Therefore, the 2023 FIGO staging system demonstrates the logical next step in the evolution of the revolution in a patient-centric staging approach. Below, we elucidate the rationale for the FIGO 2023 endometrial cancer staging system.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gaffney D, Matias-Guiu X, Mutch D, et al. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution. Gynecol Oncol. 2024. PMID: 38447389. doi:10.1016/j.ygyno.2024.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。